A protocol for a Canadian prospective observational study of decision-making on active surveillance or surgery for low-risk papillary thyroid cancer

Anna M Sawka, Sangeet Ghai, George Tomlinson, Lorne Rotstein, Ralph Gilbert, Patrick Gullane, Jesse Pasternak, Dale Brown, John de Almeida, Jonathan Irish, Douglas Chepeha, Kevin Higgins, Eric Monteiro, Jennifer M Jones, Amiram Gafni, David P Goldstein, Anna M Sawka, Sangeet Ghai, George Tomlinson, Lorne Rotstein, Ralph Gilbert, Patrick Gullane, Jesse Pasternak, Dale Brown, John de Almeida, Jonathan Irish, Douglas Chepeha, Kevin Higgins, Eric Monteiro, Jennifer M Jones, Amiram Gafni, David P Goldstein

Abstract

Introduction: Low-risk papillary thyroid cancer (PTC) is increasingly being diagnosed throughout the world; yet the mortality risk is low compared with other malignancies. Traditional management includes thyroid surgery, sometimes followed by radioactive iodine and thyroid hormone treatment. Active surveillance (AS) has been proposed as a means to reduce overtreatment of PTC. AS involves close disease follow-up, with the intention to intervene if the disease progresses, or on patient request.

Methods and analysis: This is a multiphase prospective observational study. In the first phase of this study, consenting eligible adults with low-risk PTC, that is, <2 cm in maximal diameter, confined to the thyroid and not immediately adjacent to critical structures in the neck, are provided verbal and written information about PTC disease prognosis following surgery or AS. Questionnaires are administered at baseline and after the disease management decision on AS or surgery is finalised. Patients may choose either option (surgery or AS), and the primary outcome is the frequency with which either disease management option is chosen. Secondary outcomes include: rationale for the decision, role of the patient in decision-making and decision satisfaction. In the second phase of the study, consenting eligible adult patients who completed the first study phase may enrol in respective AS or surgery group follow-up studies. The following outcomes are examined 1 year after enrolment in the follow-up phase: decision regret about disease management choice (primary outcome), psychological distress, disease-specific quality of life, fear of disease progression, body image satisfaction, disease progression, crossover to surgery in the AS group, new chronic thyroid hormone use and healthcare resource utilisation.

Ethics and dissemination: The University Health Network Research Ethics Board approved this study (ID 15-8942). The results will be published in an open access journal.

Trial registration number: NCT03271892; Pre-results.

Keywords: endocrine tumours.

Conflict of interest statement

Competing interests: None declared.

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

References

    1. Esserman LJ, Thompson IM, Reid B, et al. . Addressing overdiagnosis and overtreatment in cancer: a prescription for change. Lancet Oncol 2014;15:e234–42. 10.1016/S1470-2045(13)70598-9
    1. Cancer Research UK. Cancerstats: thyroid cancer incidence statistics. (accessed 30 Aug 2017).
    1. Canadian Cancer Society’s Advisory Committee on Cancer Statistics. Canadian cancer statistics. 2017. (accessed 30 Aug 2017).
    1. American Cancer Society: cancer facts and figures 2017. (accessed 30 Aug 2017).
    1. EUCAN (International Agency for Research on Cancer of the World Health Organization). Cancer fact sheets: thyroid cancer – both sexes. (accessed 30 Aug 2017).
    1. Guay B, Johnson-Obaseki S, McDonald JT, et al. . Incidence of differentiated thyroid cancer by socioeconomic status and urban residence: Canada 1991-2006. Thyroid 2014;24:552–5. 10.1089/thy.2013.0308
    1. Kent WD, Hall SF, Isotalo PA, et al. . Increased incidence of differentiated thyroid carcinoma and detection of subclinical disease. CMAJ 2007;177:1357–61. 10.1503/cmaj.061730
    1. Pathak KA, Leslie WD, Klonisch TC, et al. . The changing face of thyroid cancer in a population-based cohort. Cancer Med 2013;2:537–44. 10.1002/cam4.103
    1. Davies L, Welch HG. Current thyroid cancer trends in the United States. JAMA Otolaryngol Head Neck Surg 2014;140:317–22. 10.1001/jamaoto.2014.1
    1. Albores-Saavedra J, Henson DE, Glazer E, et al. . Changing patterns in the incidence and survival of thyroid cancer with follicular phenotype--papillary, follicular, and anaplastic: a morphological and epidemiological study. Endocr Pathol 2007;18:1–7. 10.1007/s12022-007-0002-z
    1. Enewold L, Zhu K, Ron E, et al. . Rising thyroid cancer incidence in the united states by demographic and tumor characteristics, 1980-2005. Cancer Epidemiology Biomarkers & Prevention 2009;18:784–91. 10.1158/1055-9965.EPI-08-0960
    1. Chen AY, Jemal A, Ward EM. Increasing incidence of differentiated thyroid cancer in the United States, 1988-2005. Cancer 2009;115:3801–7. 10.1002/cncr.24416
    1. Haugen BR, Alexander EK, Bible KC, et al. . 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the american thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 2016;26:1–133. 10.1089/thy.2015.0020
    1. Perros P, Boelaert K, Colley S, et al. . Guidelines for the management of thyroid cancer. Clin Endocrinol 2014;81(Suppl 2):1–122. 10.1111/cen.12515
    1. Pacini F, Castagna MG, Brilli L, et al. . Thyroid cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012;23(suppl 7):vii110–19. 10.1093/annonc/mds230
    1. Leboulleux S, Tuttle RM, Pacini F, et al. . Papillary thyroid microcarcinoma: time to shift from surgery to active surveillance? Lancet Diabetes Endocrinol 2016;4:933–42. 10.1016/S2213-8587(16)30180-2
    1. Brito JP, Hay ID, Morris JC. Low risk papillary thyroid cancer. BMJ 2014;348:g3045 10.1136/bmj.g3045
    1. Haymart MR, Miller DC, Hawley ST. Active surveillance for low-risk cancers — a viable solution to overtreatment? N Engl J Med Overseas Ed 2017;377:203–6. 10.1056/NEJMp1703787
    1. Sugitani I, Toda K, Yamada K, et al. . Three distinctly different kinds of papillary thyroid microcarcinoma should be recognized: our treatment strategies and outcomes. World J Surg 2010;34:1222–31. 10.1007/s00268-009-0359-x
    1. Ito Y, Miyauchi A, Kihara M, et al. . Patient age is significantly related to the progression of papillary microcarcinoma of the thyroid under observation. Thyroid 2014;24:27–34. 10.1089/thy.2013.0367
    1. Tuttle RM, Fagin JA, Minkowitz G, et al. . Natural history and tumor volume kinetics of papillary thyroid cancers during active surveillance. JAMA Otolaryngol Head Neck Surg 2017;143:1015 10.1001/jamaoto.2017.1442
    1. Oda H, Miyauchi A, Ito Y, et al. . Incidences of unfavorable events in the management of low-risk papillary microcarcinoma of the thyroid by active surveillance versus immediate surgery. Thyroid 2016;26:150–5. 10.1089/thy.2015.0313
    1. D’Agostino TA, Shuk E, Maloney EK, et al. . Treatment decision making in early-stage papillary thyroid cancer. Psychooncology 2018;27:61–8. 10.1002/pon.4383
    1. Carver CS. You want to measure coping but your protocol’s too long: consider the brief COPE. Int J Behav Med 1997;4:92–100. 10.1207/s15327558ijbm0401_6
    1. Herschbach P, Berg P, Dankert A, et al. . Fear of progression in chronic diseases: psychometric properties of the Fear of Progression Questionnaire. J Psychosom Res 2005;58:505–11. 10.1016/j.jpsychores.2005.02.007
    1. Mehnert A, Herschbach P, Berg P, et al. . [Fear of progression in breast cancer patients--validation of the short form of the Fear of Progression Questionnaire (FoP-Q-SF)]. Z Psychosom Med Psychother 2006;52:274–88.
    1. Theunissen M, Peters ML, Schouten EG, et al. . Validation of the surgical fear questionnaire in adult patients waiting for elective surgery. PLoS One 2014;9:e100225 10.1371/journal.pone.0100225
    1. Bunn H, O’Connor A. Validation of client decision-making instruments in the context of psychiatry. Can J Nurs Res 1996;28:13–27.
    1. Holmes-Rovner M, Kroll J, Schmitt N, et al. . Patient satisfaction with health care decisions: the satisfaction with decision scale. Med Decis Making 1996;16:58–64. 10.1177/0272989X9601600114
    1. Brehaut JC, O’Connor AM, Wood TJ, et al. . Feldman-Stewart D: validation of a decision regret scale. Medical Decision Making 2003;23:281–92.
    1. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983;67:361–70. 10.1111/j.1600-0447.1983.tb09716.x
    1. Gning I, Trask PC, Mendoza TR, et al. . Development and initial validation of the thyroid cancer module of the M. D. Anderson Symptom Inventory. Oncology 2009;76:59–68. 10.1159/000178809
    1. Hopwood P, Fletcher I, Lee A, et al. . A body image scale for use with cancer patients. Eur J Cancer 2001;37:189–97. 10.1016/S0959-8049(00)00353-1
    1. Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care 2003;41:582–92. 10.1097/01.MLR.0000062554.74615.4C
    1. Castro FG, Kellison JG, Boyd SJ, et al. . A methodology for conducting integrative mixed methods research and data analyses. J Mix Methods Res 2010;4:342–60. 10.1177/1558689810382916
    1. Sawka AM, Rilkoff H, Tsang RW, et al. . The rationale of patients with early-stage papillary thyroid cancer for accepting or rejecting radioactive iodine remnant ablation. Thyroid 2013;23:246–7. 10.1089/thy.2012.0422

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe